A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We provide an update on the efficacy of the quadrivalent HPV vaccine against high-grade cervical, vaginal, and vulvar lesions based...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2009
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23636
- Acceso en línea:
- https://doi.org/10.1158/1940-6207.CAPR-09-0031
https://repository.urosario.edu.co/handle/10336/23636
- Palabra clave:
- Virus DNA
Wart virus vaccine
Adolescent
Adult
Age distribution
Article
Cancer immunization
Cancer prevention
Clinical trial
Controlled clinical trial
Controlled study
Drug efficacy
Drug withdrawal
Female
Follow up
Human
Human papillomavirus type 11
Human papillomavirus type 16
Human papillomavirus type 18
Human papillomavirus type 6
Major clinical study
Multicenter study
Papanicolaou test
Phase 3 clinical trial
Priority journal
Randomized controlled trial
Sexual behavior
Smoking
Unspecified side effect
Uterine cervix cancer
Vagina cancer
Virus detection
Vulva cancer
Adolescent
Adult
Cancer Vaccines
Cervical Intraepithelial Neoplasia
Female
Human papillomavirus 11
Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 6
Humans
Multicenter Studies as Topic
Papillomavirus Infections
Papillomavirus Vaccines
Randomized Controlled Trials as Topic
Uterine Cervical Neoplasms
Young Adult
Female
Phase III as Topic
Clinical Trials
Genital Diseases
- Rights
- License
- Abierto (Texto Completo)